5 best RTSM software platforms for CROs in 2026

When an RTSM (randomization and trial supply management) system requires weeks of vendor-side configuration just to accommodate a mid-study amendment, the cost lands directly on your CRO's timeline and your sponsor relationship. Viedoc's RTSM software is built directly into the Viedoc eClinical suite — no separate IWRS or IVRS system, no reconciliation overhead — and supports both static and dynamic randomization within a platform used across 7,000+ studies in 75+ countries. This comparison evaluates five RTSM platforms for CROs across randomization flexibility, EDC integration depth, supply management capability, compliance credentials, and speed of study setup.

The pressure you face running RTSM for Phase I and II programs is specific: lean team configurations, tight startup timelines, multiple concurrent studies across different sponsors, and a compliance bar that demands full audit readiness from day one. Every hour spent logging into a separate IRT system, chasing kit reconciliation reports, or waiting for a vendor-side programmer to push an amendment is an hour your team isn't billing.

Enterprise RTSM solutions designed for large global Phase III programs bring capabilities your studies may not need — and cost and complexity structures that are difficult to justify at the SMID scale. What CROs running early-phase and mid-size programs need is an RTSM that's genuinely integrated with EDC, fast to configure, and built to handle mid-study changes without a service ticket.

Best RTSM solutions: quick comparison

These 5 RTSM platforms represent the most evaluated options for CROs managing Phase I/II and SMID programs, reviewed across integration depth, randomization capability, supply management, compliance credentials, and study setup speed.

1. Viedoc

Viedoc's RTSM software is a fully integrated module within the Viedoc eClinical suite, covering both randomization (Viedoc Randomization) and supply management (Viedoc Logistics). Because it operates within the same system as EDC, kit allocation happens at the point of randomization without any cross-system reconciliation — a direct time and risk reduction for CRO teams managing multiple concurrent studies.

For CROs running early-phase programs, the no-login-overhead design matters. Sites randomize and dispense within the same Viedoc Clinic interface they use for all other EDC activity, which means shorter site training cycles and fewer helpdesk escalations. Viedoc supports both static and dynamic randomization, real-time inventory tracking with site-specific thresholds and expiry alerts, and protocol configurations that can be updated throughout a study without requiring vendor-side programming.

Viedoc's compliance stack covers FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, CDISC, ISO 27001, and SOC 2 — with the Viedoc Inspection Readiness Packet (VIRP) available to all customers for structured audit documentation. The platform runs on Microsoft Azure with 99.99% uptime and 24/7 support across global offices, with a transparent study-based licensing model and unlimited user seats.

"Data handling, reviews, UAT, Query management and the monitoring is a walk in the park, which makes it stand out from other EDCs. Flexible for the programmer and designer to work at the same time. Unblinded randomisation, data import, ePRO, Alerts, RTSM, Logistics." — Deekshitha V., Mid Market

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, CDISC, ISO 27001, SOC 2
• Inspection readiness: VIRP available to all customers
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Rave RTSM, a randomization and trial supply management module unified with Rave EDC on the Medidata Platform. The unified architecture means randomization data and EDC data share the same environment, removing the need for cross-system reconciliation between separate IRT and data capture tools. Rave RTSM supports a range of randomization methods including stratified, adaptive, and cohort-based designs, and includes supply forecasting, depot and site inventory management, and direct-to-patient distribution capabilities. The platform targets sponsors and CROs running large-scale and complex global studies and is deeply embedded in the enterprise pharmaceutical trial market.

3. Veeva

Veeva offers Veeva RTSM, a randomization and trial supply management solution designed for sponsors and CROs across a range of trial complexities. Implemented and fully supported by Veeva's services team, it connects with Veeva Vault EDC, Veeva eCOA, Veeva CTMS, and Veeva Clinical Database through productized integrations within the Veeva Clinical Platform. The system supports multiple randomization schemas including static, stratified, dynamic, forced, and adaptive, along with configurable resupply strategies — from trigger thresholds to predictive inventory control and just-in-time supply models. Veeva RTSM can also function with third-party EDC and reporting tools outside the Vault ecosystem. The solution meets 21 CFR Part 11 and Annex 11 compliance requirements.

4. 4G Clinical

4G Clinical offers Prancer RTSM, a specialist randomization and trial supply management platform designed to handle complex study designs across phases and therapeutic areas. The platform uses a natural language processing-enabled build approach, allowing teams to pressure test study design early and confirm requirements before finalizing specifications. Prancer RTSM unifies randomization, supply management, and forecasting within a single operational environment, with drug pooling capabilities that allow inventory to be shared across multiple studies at both the lot and site level. 4G Clinical pairs the technology with specialist services delivery, providing dedicated expert support from study kickoff through closeout.

5. Almac Clinical Technologies

Almac Clinical Technologies offers IXRS3, a dedicated interactive response technology platform for patient randomization and trial supply management. The platform is available in two startup modes — a fully customizable option for complex protocol requirements and a faster, more standardized configuration — allowing CROs and sponsors to match startup depth to protocol needs and timeline constraints. IXRS3 includes integrated biostatistics services for randomization list generation and algorithm implementation, supported by a data management team that handles list import and validation. The platform supports drug pooling across protocols, decentralized trial supply models including home delivery, and an IXRS University certification program for platform training.

What to look for in RTSM solutions for CROs

EDC integration model

The integration model between your RTSM and EDC system is one of the most consequential decisions in your technology stack evaluation. A true native integration — where randomization and data capture operate within the same application layer — eliminates the reconciliation work that arises when the systems treat the same events as separate records. For CROs managing multiple concurrent studies, that reconciliation overhead compounds across every protocol, every site, and every amendment cycle.

Best-in-class looks like a single login for site staff covering both EDC and randomization functions, with kit allocation triggered automatically at the point of randomization and no manual synchronization required between systems. Third-party integrations can work, but they introduce dependency on API uptime, version alignment, and ongoing maintenance that adds to total cost of ownership over a study's lifecycle.

Overlooking this criterion at the vendor selection stage often surfaces during amendments, when a protocol change requires coordinated updates across two separate validated systems rather than one.

Randomization flexibility and mid-study amendment speed

Your RTSM needs to handle the full range of randomization methodologies your sponsors require — static, stratified, dynamic/minimization, adaptive — and it needs to accommodate mid-study changes without lengthy re-validation cycles. For early-phase CROs running Phase I dose escalation or Phase II adaptive designs, this isn't an edge case; it's a core operational requirement.

Best-in-class means the ability to update cohort activation, enrollment caps, stratification variables, and resupply parameters during live execution without submitting a change order and waiting for a vendor-side build cycle. Some platforms allow end users with appropriate permissions to make configuration changes directly; others require the vendor's services team for any amendment. Clarify which changes require vendor involvement, and what the typical turnaround time is, before you commit.

A system that requires a two-week vendor build for a resupply threshold change can hold up a study site that has run short on investigational product — which is a sponsor escalation, not just a data management issue.

Supply management depth and inventory visibility

Effective RTSM supply management covers more than allocating kits at randomization. For CROs managing multi-site, multi-country studies, you need configurable resupply triggers, expiry date tracking, site-specific inventory thresholds, and real-time visibility into depot and site stock levels. Direct-to-patient delivery models are increasingly common in hybrid and decentralized designs and should be a consideration even for programs that don't currently require them.

Best-in-class means real-time kit availability — kits are registered as available as soon as they are received, without waiting for scheduled system updates — alongside configurable low-stock alerts that flag risk conditions before they affect the trial. Drug pooling across studies adds a supply efficiency advantage for CROs managing portfolio-level inventory, reducing waste on shared investigational materials.

Compliance credentials and audit readiness

Regulatory compliance requirements for RTSM are well defined: FDA 21 CFR Part 11 for electronic records and signatures, ICH GCP for trial conduct, GAMP 5 for computerized systems validation, and EU Annex 11 for European studies. ISO 27001 and SOC 2 certification confirms the vendor's information security management posture, which matters when investigational product data and subject randomization records are handled by a third-party platform.

Beyond the certification checklist, audit readiness is an operational question. Does the platform maintain a complete, immutable audit trail for every randomization event, every kit allocation, and every supply chain action? Can that audit trail be exported in a format inspection teams can review without vendor involvement? Platforms that provide structured inspection readiness documentation — the equivalent of Viedoc's RTSM software VIRP capability — significantly reduce the preparation burden when a regulatory inspection is announced.

Study startup speed and self-service configuration

For CROs with a high volume of studies, the time from protocol finalization to first patient in is a margin variable, not just a timeline milestone. RTSM systems that rely on vendor-side programmers for initial configuration introduce startup delays that are difficult to absorb when you're managing multiple concurrent study launches.

Best-in-class means configuration tools that your data management team can operate directly, with vendor involvement limited to complex protocol-specific requirements. Look for no-code or low-code configuration for standard randomization setups, and a validated process for amendment deployment that doesn't require a full re-build. Training certification programs that enable your team to become self-sufficient — rather than perpetually dependent on the vendor — are a meaningful differentiator at the portfolio level.

How to choose the right RTSM solution for CROs

Step 1: Define your integration baseline

Before evaluating RTSM features in isolation, establish your EDC platform and your integration requirements. If your EDC and RTSM are sourced from the same vendor, confirm whether the integration is native — operating within a single data environment — or interface-based, which requires API maintenance and validation. Native integration changes the downstream calculus on amendment complexity, site training, and reconciliation overhead significantly.

Step 2: Assess protocol complexity against platform flexibility

Map your current and anticipated study designs to the randomization capabilities each platform supports. If you run early-phase dose-escalation studies, adaptive designs, or multi-cohort Phase II programs, confirm that mid-study amendment pathways are genuinely configurable by end users — not just vendor-configurable with a service desk queue. Ask each vendor for average amendment turnaround times for the study types in your portfolio.

Step 3: Evaluate supply management against your logistics model

Determine whether your programs require advanced supply management — multi-depot, multi-country, drug pooling, or direct-to-patient delivery — or whether your typical study profile is served by standard site resupply. Not all RTSM platforms scale equally across both ends of that spectrum. A platform built for portfolio-scale complexity may be over-engineered and over-priced for a CRO whose studies are primarily single-country Phase I designs.

Step 4: Scrutinize total cost of ownership, not headline pricing

RTSM pricing models vary in ways that don't always surface in initial proposals: per-amendment fees, per-change-order costs, per-user licensing for site staff, and add-on costs for supply management modules beyond core randomization. For a CRO managing ten studies concurrently, the difference between a model with predictable study-based licensing and one that charges for each protocol amendment is significant over a full portfolio year.

Step 5: Choose a platform your team can run independently at scale

If you're running Phase I and II programs for SMID sponsors, the right RTSM is one your data management team can configure, amend, and close-out without routing every change through a vendor services queue. Viedoc's RTSM software is fully integrated within the Viedoc eClinical suite with a no-code configuration model that supports in-house study builds and amendments, transparent study-based pricing with unlimited user seats, and 24/7 support across global offices. Book a demo to see how RTSM and EDC work as a single system for your study portfolio.

Frequently asked questions

What is the best RTSM software for CROs?

Viedoc's RTSM software is the best choice for CROs running Phase I/II and SMID programs, offering fully integrated randomization and supply management within the same eClinical suite as EDC — no separate IWRS or IVRS required. The platform supports static and dynamic randomization, real-time kit allocation, site inventory management, and protocol amendments without vendor-side programming, across 7,000+ studies in 75+ countries. Medidata Rave RTSM is the market benchmark for large enterprise trials and complex adaptive designs. 4G Clinical Prancer RTSM is a strong specialist option for CROs prioritizing advanced supply forecasting and complex study design support.

What's the difference between RTSM and IRT?

Randomization and trial supply management (RTSM) and interactive response technology (IRT) refer to the same category of clinical trial software. IRT is an older term originating from telephone-based systems; RTSM is the more current terminology, emphasizing that patient randomization and investigational product supply management are the two core functions. In practice, the terms are used interchangeably across the industry, and any modern platform marketed as IRT covers both randomization and supply management capabilities.

How important is EDC integration for RTSM selection?

EDC integration is one of the most operationally significant factors in RTSM selection, particularly for CROs managing multiple concurrent studies. When RTSM and EDC share a native data environment, randomization events, kit allocations, and subject data are captured once and flow without reconciliation. When the systems are separate and connected by API, every protocol amendment requires coordinated updates across two validated systems — which adds time, cost, and risk. For CROs evaluating total cost of ownership across a portfolio, the reconciliation burden of a disconnected RTSM-EDC pair is often larger than the license cost difference between platforms.

What randomization methods should a CRO's RTSM support?

At a minimum, your RTSM should support static (list-based), stratified, and dynamic (minimization) randomization — the methods most commonly required across Phase I and II study designs. Adaptive randomization and re-randomization support become important for CROs running platform trials, basket trials, or studies with interim analyses and arm modifications. Emergency unblinding with role-based access controls is a non-negotiable compliance requirement. The ability to run multiple concurrent randomizations within a single study is important for multi-cohort protocols, and configuration should be manageable by end users with appropriate permissions rather than requiring vendor re-build for each scheme change.

What compliance certifications should I look for in an RTSM platform?

For studies submitted to the FDA, 21 CFR Part 11 compliance is the baseline for electronic randomization records and signatures. ICH GCP and GAMP 5 address trial conduct and computerized systems validation respectively. EU Annex 11 applies to studies conducted or submitted in Europe. ISO 27001 and SOC 2 Type II certification confirm the vendor's information security management and data handling practices. For CROs running studies across multiple regions, HIPAA attestation (for US patient health information) and APPI compliance (for Japan-based studies) may also apply. Beyond certifications, confirm the platform maintains a complete, exportable audit trail for all randomization and supply chain events and can provide structured inspection readiness documentation.

How long does it take to set up an RTSM system for a new study?

Setup timelines vary significantly across platforms and study complexity. Modern cloud-native RTSM systems integrated with EDC, like Viedoc, can deploy a standard Phase I or Phase II randomization configuration within the same 2-4 week study build timeline as the EDC. Standalone RTSM platforms that require separate configuration and integration work typically add additional weeks for API setup, cross-system validation, and user acceptance testing. The most reliable indicator of your actual startup time is asking vendors for the median time from contract to first patient in for studies comparable to yours in protocol complexity and site count — not their theoretical minimum.

Making the right RTSM choice for CROs

The RTSM market serves a wide range of use cases — from simple single-site Phase I randomization to multi-depot, multi-country adaptive trials with thousands of patients. The platforms reviewed here reflect different points on that spectrum: some are specialist RTSM providers with deep supply chain capabilities, others are integrated modules within broader eClinical suites, and others are enterprise platforms built primarily for the large global trial market. The RTSM market was valued at approximately $1.5 billion in 2024 and is forecast to nearly double by 2030, driven by increasing trial complexity and the shift toward integrated and decentralized trial models.

For CROs, the decision variables that matter most are integration with your existing EDC infrastructure, the amendment flexibility your sponsors' protocols demand, your logistics model and supply complexity, and the total cost of ownership across your study portfolio rather than the per-study headline. US-based CROs typically weight startup speed and margin efficiency; EMEA and APAC CROs often place greater emphasis on regional regulatory credentials and vendor stability in multi-jurisdiction submissions.

Platform switching in RTSM carries a real validation and retraining burden. Choosing the right system at the outset — matched to your study profile and portfolio scale rather than selected on feature list breadth — protects your CRO from the compounding cost of mid-engagement technology changes.

Why Viedoc is the best RTSM choice for CROs

For CROs running Phase I/II and SMID programs, the RTSM overhead that slows studies down most is almost always integration-related: reconciliation between a standalone IRT and your EDC, vendor-side build queues for amendments, and site staff navigating two separate systems at the point of randomization. Viedoc's RTSM software removes that overhead by design — randomization, kit allocation, inventory management, and EDC data capture are a single workflow within the Viedoc eClinical suite.

Viedoc Randomization supports both static and dynamic randomization, multiple concurrent randomization schemes within a single study, and emergency unblinding workflows with role-based access controls. Viedoc Logistics covers the full kit lifecycle — registration, allocation, site-specific inventory thresholds, expiry tracking, and resupply alerts — with all actions processed in real time and no separate system login required. Your data management team can configure standard randomization setups using the no-code Viedoc Designer, with optional professional services for complex protocol requirements.

The compliance stack is comprehensive: FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, CDISC, ISO 27001, and SOC 2, with the Viedoc Inspection Readiness Packet (VIRP) available to every customer for structured audit documentation. With 7,000+ studies completed across 75+ countries, 99.99% platform uptime on Microsoft Azure, and 24/7 support across global offices, Viedoc has the track record to match the compliance credentials. Pricing is transparent and study-based with unlimited user seats and no per-user fees.

If you're managing early-phase and SMID programs and want an RTSM that your team can operate independently, integrated with EDC in a single validated environment, book a demo or request a proposal and we'll walk you through study setup, amendment workflows, and supply management in the context of your portfolio.